144 related articles for article (PubMed ID: 9694550)
1. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
4. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
5. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Berger K; Klose G; Szucs TD
Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070
[TBL] [Abstract][Full Text] [Related]
6. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
7. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
Morris S
Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
[TBL] [Abstract][Full Text] [Related]
8. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Glasziou PP; Simes RJ; Hall J; Donaldson C
Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
[TBL] [Abstract][Full Text] [Related]
9. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
11. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
15. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
20. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
Caro J; Klittich W; McGuire A; Ford I; Pettitt D; Norrie J; Shepherd J
Eur Heart J; 1999 Feb; 20(4):263-8. PubMed ID: 10099920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
